文献速递妇科

卵巢癌患者接受血管内皮生长因子受体酪氨酸激酶抑制剂治疗后的腹泻评估与管理

Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2018-04-05

综述探讨卵巢癌患者接受血管内皮生长因子受体酪氨酸激酶抑制剂(VEGFR-TKI)治疗后腹泻的可能机制与干预措施,涵盖疾病相关、治疗相关及饮食相关原因,并提供腹泻治疗流程供临床参考。

要点

  • VEGFR-TKI可单药、联合PARP抑制剂或联合/序贯细胞毒化疗用于卵巢癌。
  • 腹泻是该类药物最常见毒性之一,需评估疾病、治疗及饮食相关原因。
  • 文中提供腹泻治疗流程作为卵巢癌患者VEGFR-TKI治疗相关腹泻的临床参考。

核心结论

  • 若VEGFR-TKI获批用于卵巢癌,患者需对腹泻等不良事件进行及时有效管理以优化依从性和获益。

研究设计与样本

  • 综述概述VEGFR-TKI诱导腹泻的可能机制、潜在干预措施并提供腹泻治疗流程。

主要发现

  • 腹泻是该类药物最常见毒性之一,原因包括疾病相关(肠梗阻)、治疗相关(VEGFR-TKI相关或细胞毒化疗联合VEGFR抑制剂时的感染性/中性粒细胞减少性脓毒症腹泻)或饮食相关。

临床怎么用

  • 作者提供腹泻治疗流程,作为卵巢癌患者接受VEGFR-TKI联合化疗或PARP抑制剂或单药治疗时腹泻管理的临床参考点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Angiogenesis is a proven clinical target for the treatment of advanced epithelial ovarian cancer. Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) offer patients potential new treatment regimens as they can be given as monotherapy, in combination with poly(ADP-ribose) polymerase (PARP) inhibitors, or with and following cytotoxic chemotherapy. If VEGFR-TKIs are licensed for use in ovarian cancer, patients will require prompt and effective management of adverse events, including diarrhea, to optimize compliance and benefit. As diarrhea is one of the most prevalent toxicities of this class of drug, it is important to consider the potential causes, be they disease related (bowel obstruction), treatment related (VEGFR-TKI-related or infective/neutropenic septic diarrhea when patients are receiving cytotoxic chemotherapy combined with VEGFR inhibitor treatment), or incurred through diet. Here, we provide an overview of the possible mechanisms responsible for VEGFR-TKI-induced diarrhea. We review potential interventions that can help in the management of diarrhea induced by VEGFR-TKIs, when used in combination or as single agents, and we provide a diarrhea treatment algorithm to serve as a clinical reference point for the management of diarrhea in patients with ovarian cancer treated with a VEGFR-TKI in combination with chemotherapy or PARP inhibitors, or as monotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Liu J, Nicum S, Reichardt P, et al. Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. Gynecol Oncol. 2018. PMID: 29627080. doi:10.1016/j.ygyno.2018.03.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。